

## Neointima formation after vascular injury: Is it all about CD39?

Pallavi Subramanian; Andreas Schober

Institute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Aachen, Germany

Since the pioneering era of interventional cardiology, platelet deposition after vascular injury has been regarded of central importance for neointima formation and subsequent restenosis (1–3). Depending on the type of injury, i.e. how many layers of the vessel wall are affected, surface-adherent platelets can be distinguished from mural thrombus extending into the torn media (4). Whereas organised thrombi can sometimes cause occlusion and restenosis, platelets adherent to the subendothelial matrix constitute the main adhesive substrate for the recruitment of leukocytes and smooth muscle progenitor cells to the injury site driving neointimal growth (5–8). P-selectin expressed on activated platelets, rather than platelet aggregation, is decisively involved through mediating adhesive interactions and the deposition of pro-inflammatory chemokines in a PSGL-1-dependent manner (9–12). In contrast to the compelling experimental evidence, however, most antiplatelet compounds have hitherto failed to prevent neointimal hyperplasia in the clinical setting (13–15). This mandates a search for new antiplatelet strategies, which specifically target platelet functions involved in the response to vascular injury (16, 17).

In the current issue of *Thrombosis and Haemostasis*, Drosopoulos et al. evaluated the role of a recombinant and soluble form of human CD39 (solCD39) in a murine model of neointima formation after wire-induced denudation of the femoral artery

by targeting platelet function (18). CD39 is a cell surface ADPase expressed on leukocytes and endothelial cells, which degrades nucleotides tri- and/or diphosphates and thereby terminates the aggregation response of platelets to adenosine diphosphate (19). The isolation of a 439 amino acid polypeptide from the extracellular domain of CD39 yielded an injectable protein which retained ATPase activity *in vivo* (20). The most astonishing finding of Drosopoulos et al. is the complete suppression of neointima formation and the absence of vascular inflammation, as evident by VCAM-1 expression and macrophage recruitment, after 19 days in solCD39-treated mice, indicating a highly active pharmacological compound in this disease model (18). Moreover, Drosopoulos et al. found that solCD39 treatment basically preserved the vessel wall architecture enclosing re-endothelialisation. These findings are in line with reports demonstrating a protective role of CD39 locally over-expressed at the injury site in neointima formation (21, 22). The infusion of solCD39, however, obviates gene transfer as a therapeutic approach making it much more attractive. Of note, CD39<sup>-/-</sup> mice have recently been shown to be also protected from neointimal hyperplasia (23), which might be explained by purinergic type P2Y1 receptor desensitisation responsible for platelet hypofunction in CD39<sup>-/-</sup> mice (24).

As one might have deduced from the well established antithrombotic activity of CD39, Drosopoulos et al. reported an absence of mural thrombus formation in solCD39-treated mice, although platelets lining the luminal wall were still present. In addition, platelet P-selectin expression was markedly reduced by solCD39, which might account for the diminished recruitment of monocytes/macrophages to the injured artery. However, even in P-selectin<sup>-/-</sup> mice, neointima formation is detectable at least to some degree, suggesting additional CD39-dependent mechanisms (10). Apoptosis of medial smooth muscle cells is a very

early event after vascular injury (25). Recently, caspase-dependent release of ATP has been shown to induce monocyte recruitment, which can be prevented by ectopic CD39 (26). In mice deficient in CD73/ecto-5'-nucleotidase, which sequentially catalyses the conversion of AMP to adenosine, neointima formation is significantly increased due to constitutive NF-κB activation in the absence of adenosine (27). Furthermore, the absence of the A2 adenosine receptors on bone marrow cells exacerbated neointimal growth after femoral wire-injury probably by controlling CXCR4 expression (28). In this regard, it would be interesting to examine whether the beneficial effect of solCD39 on neointima formation is impeded in CD73<sup>-/-</sup> mice. Some caveats remain in the study by Drosopoulos et al. and need to be further explored. This includes the decline of the ADPase activity after 17 days of treatment, which was assigned to a neutralizing immune response by the authors. Since the mice in the control group were only treated with saline, but not with inactive solCD39, the contribution of an elicited anti-CD39 immune response to the observed effect is a matter of debate.

Thus, solCD39 infusion appears to be a valuable new anti-platelet strategy in the prevention of restenosis potentially harbouring some collateral effects associated with its potent anti-inflammatory properties. Nevertheless, future studies are warranted to fully address the mechanisms of the “holistic” impact of solCD39, before it can reach the potential status of a novel “magic bullet” in restenosis research.

### Correspondence to:

Prof. Andreas Schober  
Institute for Molecular Cardiovascular Research (IMCAR)  
University Hospital Aachen, RWTH Aachen University  
Pauwelsstr. 30  
52074 Aachen, Germany  
Tel.: +49 241 80 855 28, Fax: +49 241 80 827 16  
E-mail: aschober@ukaachen.de

Received: January 4, 2010

Accepted: January 4, 2010

Prepublished online: January 13, 2010

doi:10.1160/TH10-01-0004

Thromb Haemost 2010; 103: 257–258

## References

1. Ip JH, Fuster V, Israel D, et al. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. *J Am Coll Cardiol* 1991; 17 (6 Suppl B): 77B-88B.
2. Friedman RJ, Stemberman MB, Wenz B, et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits. *Smooth*

Thrombosis and Haemostasis 103.2/2010

- muscle cell proliferation and re-endothelialization. *J Clin Invest* 1977; 60: 1191–1201.
3. Fingerle J, Johnson R, Clowes AW, et al. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. *Proc Natl Acad Sci USA* 1989; 86: 8412–8416.
  4. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. *Circ Res* 1985; 57: 105–112.
  5. Nobuyoshi M, Kimura T, Ohishi H, et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. *J Am Coll Cardiol* 1991; 17: 433–439.
  6. Schober A, Zerneck A. Chemokines in vascular remodeling. *Thromb Haemost* 2007; 97: 730–737.
  7. Schober A, Zerneck A, Liehn EA, et al. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. *Circ Res* 2004; 95: 1125–1133.
  8. Zerneck A, Schober A, Bot I, et al. SDF-1 $\alpha$ /CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. *Circ Res* 2005; 96: 784–791.
  9. Tanguay JF, Geoffroy P, Sirois MG, et al. Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1. *Thromb Haemost* 2004; 91: 1186–1193.
  10. Smyth SS, Reis ED, Zhang W, et al. Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. *Circulation* 2001; 103: 2501–2507.
  11. Schober A, Manka D, von Hundelshausen P, et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. *Circulation* 2002; 106: 1523–1529.
  12. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. *Thromb Haemost* 2007; 97: 704–713.
  13. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. *Circulation* 1999; 100: 799–806.
  14. Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. *N Engl J Med* 1988; 318: 1714–1719.
  15. Savage MP, Goldberg S, Bove AA, et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). *Circulation* 1995; 92: 3194–3200.
  16. Munnix IC, Cosemans JM, Auger JM, et al. Platelet response heterogeneity in thrombus formation. *Thromb Haemost* 2009; 102: 1149–1156.
  17. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. *Thromb Haemost* 2009; 102: 248–257.
  18. Drosopoulos JH, Kraemer R, Shen H, et al. Human solCD39 inhibits injury-induced development of neointimal hyperplasia. *Thromb Haemost* 2009; 103: 426–434.
  19. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. *J Clin Invest* 1997; 99: 1351–1360.
  20. Gayle RB, 3rd, Maliszewski CR, Gimpel SD, et al. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. *J Clin Invest* 1998; 101: 1851–1859.
  21. Takemoto Y, Kawata H, Soeda T, et al. Human placental ectonucleoside triphosphate diphosphohydrolase gene transfer via gelatin-coated stents prevents in-stent thrombosis. *Arterioscler Thromb Vasc Biol* 2009; 29: 857–862.
  22. Koziak K, Bojakowska M, Robson SC, et al. Overexpression of CD39/nucleoside triphosphate diphosphohydrolase-1 decreases smooth muscle cell proliferation and prevents neointima formation after angioplasty. *J Thromb Haemost* 2008; 6: 1191–1197.
  23. Behdad A, Sun X, Khalpey Z, et al. Vascular smooth muscle cell expression of ectonucleotidase CD39 (ENTPD1) is required for neointimal formation in mice. *Purinergic Signal* 2009; 5: 335–342.
  24. Enjoji K, Sevigny J, Lin Y, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. *Nat Med* 1999; 5: 1010–1017.
  25. Schober A. Chemokines in vascular dysfunction and remodeling. *Arterioscler Thromb Vasc Biol* 2008; 28: 1950–1959.
  26. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. *Nature* 2009; 461: 282–286.
  27. Zerneck A, Bidzhekov K, Ozuyaman B, et al. CD73/ecto-5'-nucleotidase protects against vascular inflammation and neointima formation. *Circulation* 2006; 113: 2120–2127.
  28. Yang D, Koupenova M, McCrann DJ, et al. The A2b adenosine receptor protects against vascular injury. *Proc Natl Acad Sci USA* 2008; 105: 792–796.